1250.1 – Diagnostic fluorescence in situ hybridisation (FISH) testing for Anaplastic Lymphoma Kinase (ALK) in advanced non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment (co-dependent). (Resubmission)

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type Re-application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Supported

Application details

Reason for application

-

Service or technology in this application

ALK FISH testing identifies tumours that carry the ALK rearrangement obtained from patients with advanced NSCLC. Subsidy from the Pharmaceutical Benefits Scheme is also being sought for crizotinib for the treatment of patients with the ALK rearrangement.

Medical condition this application addresses

ALK-positive advanced NSCLC.

Previous applications

Meetings to consider this application

  • PASC meeting: -
  • ESC meeting: 12 to 13 June 2014
  • MSAC meeting: 
    • 3 October 2014
    • 26 to 28 November 2014